Revenue CAGR:31.93%(TTM)
Based on reported financial statement history.
Over longer horizons, Revenue CAGR averages 28.47% over 3 years and 24.79% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Revenue CAGR measures how the company's top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
PODD Revenue CAGR Chart
Insulet Corp. (PODD)
PODD Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
PODD Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $2.07B | $2.71B | +$636.50M | +30.73% | +30.73% |
| 2024 | $1.70B | $2.07B | +$374.50M | +22.07% | +22.07% |
| 2023 | $1.31B | $1.70B | +$391.80M | +30.02% | +30.02% |
| 2022 | $1.10B | $1.31B | +$206.50M | +18.79% | +18.79% |
| 2021 | $904.40M | $1.10B | +$194.40M | +21.49% | +21.49% |
| 2020 | $738.20M | $904.40M | +$166.20M | +22.51% | +22.51% |
| 2019 | $563.82M | $738.20M | +$174.38M | +30.93% | +30.93% |
| 2018 | $463.77M | $563.82M | +$100.06M | +21.57% | +21.57% |
| 2017 | $366.99M | $463.77M | +$96.78M | +26.37% | +26.37% |
| 2016 | $263.89M | $366.99M | +$103.10M | +39.07% | +39.07% |
| 2015 | $288.72M | $263.89M | $-24.83M | -8.60% | -8.60% |
| 2014 | $247.08M | $288.72M | +$41.64M | +16.85% | +16.85% |
| 2013 | $211.37M | $247.08M | +$35.72M | +16.90% | +16.90% |
| 2012 | $152.25M | $211.37M | +$59.11M | +38.83% | +38.83% |
| 2011 | $96.97M | $152.25M | +$55.29M | +57.02% | +57.02% |
| 2010 | $66.03M | $96.97M | +$30.93M | +46.85% | +46.85% |
| 2009 | $36.06M | $66.03M | +$29.97M | +83.12% | +83.12% |
| 2008 | $13.37M | $36.06M | +$22.69M | +169.66% | +169.66% |
| 2007 | $3.66M | $13.37M | +$9.71M | +265.06% | +265.06% |
| 2006 | $50.00K | $3.66M | +$3.61M | +7226.00% | +7226.00% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $761.70M | -2.8% | +33.9% |
| Q4 2025 | $783.80M | +11.0% | +31.2% |
| Q3 2025 | $706.30M | +8.8% | +29.9% |
| Q2 2025 | $649.10M | +14.1% | +32.9% |
| Q1 2025 | $569.00M | -4.8% | +28.8% |
| Q4 2024 | $597.50M | +9.9% | +17.2% |
| Q3 2024 | $543.90M | +11.3% | +25.7% |
| Q2 2024 | $488.50M | +10.6% | +23.2% |
| Q1 2024 | $441.70M | -13.4% | +23.3% |
| Q4 2023 | $509.80M | +17.8% | +37.9% |
| Q3 2023 | $432.70M | +9.1% | +27.0% |
| Q2 2023 | $396.50M | +10.7% | +32.4% |
| Q1 2023 | $358.10M | -3.1% | +21.2% |
| Q4 2022 | $369.70M | +8.5% | +20.1% |
| Q3 2022 | $340.80M | +13.8% | +23.7% |
| Q2 2022 | $299.40M | +1.4% | +13.8% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy